Recent Updates
Recently added Catalysts
LENZ Positive Sentiment Score: 75/100

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Key Takeaway: LENZ Therapeutics, a biopharmaceutical company, will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. The company's management will provide corporate presentations and engage in one-on-one meetings with potential investors to discuss their aceclidine-based eye drop, LNZ100, designed to improve near vision in presbyopia patients. The FDA has set a target action date of August 8, 2025, for LNZ100, suggesting the company is advancing towards commercialization.

Market Sentiment Analysis

POSITIVE FACTORS

  • LENZ Therapeutics is preparing for significant investor engagement.
  • The participation in two prominent health care conferences highlights confidence in their product and business strategy.
  • The FDA has assigned a PDUFA target action date indicating progress in their regulatory process for LNZ100.

Full Press Release Details

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
TD Cowen 45th Annual Health Care Conference (Boston, MA)
Management is scheduled to provide a corporate presentation at Monday, March 3rd, 2025 at 9:50am ET, and will participate in one-on-one meetings from Monday, March 3rd through Wednesday, March 5th, 2025.
Leerink Partners Global Healthcare Conference (Miami, FL)
Management is scheduled to participate in a fireside chat on Tuesday, March 11th at 2:20pm ET and will participate in one-on-one meetings.
A live audio webcast of the TD Cowen 45th Annual Health Care Conference presentation can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 12 months following the event.
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ’s product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day”. LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.

Frequently Asked Questions

What is LENZ Therapeutics focused on?

LENZ Therapeutics focuses on developing aceclidine-based eye drops for presbyopia.

When will LENZ present at the TD Cowen conference?

LENZ management will present on March 3rd, 2025, at 9:50am ET.

What is the PDUFA target date for LNZ100?

The PDUFA target action date for LNZ100 is August 8, 2025.

Where is LENZ Therapeutics headquartered?

LENZ Therapeutics is headquartered in San Diego, California.

What condition does LNZ100 target?

LNZ100 is designed to treat presbyopia, affecting 1.8 billion people globally.

Last updated: Feb 24, 2025